Literature DB >> 7935575

Amphotericin B refractory aspergillosis after itraconazole: evidence for significant antagonism.

A Schaffner1, A Böhler.   

Abstract

Failure of amphotericin B to halt aspergillosis in a patient previously treated with itraconazole raised the question of whether amphotericin B lost its activity as a result of antagonism between the two antifungal drugs. Azoles exhaust the target of amphotericin B on the fungal cell membrane. Accordingly amphotericin B in vitro lost its activity against six isolates of Aspergillus fumigatus after exposure to subfungicidal concentrations of itraconazole. Prior treatment of mice with itraconazole abolished the protective effect of amphotericin B, even when itraconazole was stopped before starting amphotericin B therapy. These observations raise concern about sequential therapy of aspergillosis with itraconazole followed by amphotericin B.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7935575     DOI: 10.1111/j.1439-0507.1993.tb00732.x

Source DB:  PubMed          Journal:  Mycoses        ISSN: 0933-7407            Impact factor:   4.377


  26 in total

Review 1.  Antifungal prophylaxis during neutropenia and immunodeficiency.

Authors:  O Lortholary; B Dupont
Journal:  Clin Microbiol Rev       Date:  1997-07       Impact factor: 26.132

2.  Challenges in designing animal studies to detect antagonism of polyene activity.

Authors:  Russell E Lewis; Dimitrios P Kontoyiannis; Dimitrios P Kantoyiannis
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

Review 3.  Localised invasive sino-orbital aspergillosis: characteristic features.

Authors:  J A Sivak-Callcott; N Livesley; R A Nugent; S L Rasmussen; P Saeed; J Rootman
Journal:  Br J Ophthalmol       Date:  2004-05       Impact factor: 4.638

Review 4.  Antifungal agents: in vitro susceptibility testing, pharmacodynamics, and prospects for combination therapy.

Authors:  A H Groll; H Kolve
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-03-11       Impact factor: 3.267

Review 5.  Combination antifungal therapy.

Authors:  Melissa D Johnson; Conan MacDougall; Luis Ostrosky-Zeichner; John R Perfect; John H Rex
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

Review 6.  Aspergillus infections in transplant recipients.

Authors:  Nina Singh; David L Paterson
Journal:  Clin Microbiol Rev       Date:  2005-01       Impact factor: 26.132

7.  Efficacy of LY303366 against amphotericin B-susceptible and -resistant Aspergillus fumigatus in a murine model of invasive aspergillosis.

Authors:  P E Verweij; K L Oakley; J Morrissey; G Morrissey; D W Denning
Journal:  Antimicrob Agents Chemother       Date:  1998-04       Impact factor: 5.191

8.  Itraconazole preexposure attenuates the efficacy of subsequent amphotericin B therapy in a murine model of acute invasive pulmonary aspergillosis.

Authors:  Russell E Lewis; Randall A Prince; Jingduan Chi; Dimitrios P Kontoyiannis
Journal:  Antimicrob Agents Chemother       Date:  2002-10       Impact factor: 5.191

9.  Assessment of antifungal activities of fluconazole and amphotericin B administered alone and in combination against Candida albicans by using a dynamic in vitro mycotic infection model.

Authors:  R E Lewis; B C Lund; M E Klepser; E J Ernst; M A Pfaller
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

10.  Comparative pharmacodynamic interaction analysis of triple combinations of caspofungin and voriconazole or ravuconazole with subinhibitory concentrations of amphotericin B against Aspergillus spp.

Authors:  Joanne P Demchok; Joseph Meletiadis; Emmanuel Roilides; Thomas J Walsh
Journal:  Mycoses       Date:  2009-03-07       Impact factor: 4.377

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.